A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström Syndrome

Trial Profile

A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Alstrom's Syndrome
  • Focus Adverse reactions
  • Sponsors ProMetic Biosciences
  • Most Recent Events

    • 12 Apr 2018 Results published in a ProMetic Life Sciences media release Media Release.
    • 12 Apr 2018 According to a ProMetic Life Sciences media release, new data were presented at The International Liver Congres 2018, the annual meeting of the European Association for the Study of the Liver (EASL).
    • 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top